MMEL1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MMEL1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using MMEL1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using MMEL1 mouse mAb with DAB staining.    

  
  

MMEL1 (Membrane Metalloendopeptidase-Like 1), also known as NL1 or NEP2. is a zinc-dependent metalloprotease belonging to the neprilysin (NEP) family. It shares structural homology with neprilysin (NEP/MME), including conserved catalytic motifs and transmembrane domains. Primarily expressed in the brain, kidneys, and testes, MMEL1 is implicated in regulating neuropeptides and bioactive peptides through proteolytic processing. Studies suggest its involvement in modulating amyloid-β (Aβ) peptide levels, linking it to Alzheimer’s disease pathogenesis. Unlike NEP, MMEL1 exists in both membrane-bound and soluble forms due to alternative splicing, which may influence its substrate specificity and cellular localization.

MMEL1 antibodies are essential tools for investigating its expression, localization, and function. They enable detection via techniques like Western blot, immunohistochemistry, and immunofluorescence, aiding studies on its role in neurological disorders, cancer, and other diseases. Research using MMEL1 antibodies has revealed altered expression in Alzheimer’s models and certain tumors, highlighting its potential as a therapeutic target or biomarker. However, the antibody’s utility depends on specificity validation, as cross-reactivity with other NEP family members can occur. Overall, MMEL1 antibodies contribute to understanding its biological significance and therapeutic potential in proteostasis-related pathologies.